Focus: Tempus is an AI-driven biotech company focused on drug discovery and medical devices across oncology, gastroenterology, ophthalmology, neurology, and cardiovascular indications. The company operates as a mid-stage biotech leveraging machine learning platforms to accelerate development timelines.
Profile data last refreshed 18h ago · AI intelligence enriched 3mo ago
Hot — 152 jobs added in 30d
Net +82 (152 new, 70 removed). Aggressive expansion phase.
Best suited for data scientists, AI engineers, and real-world evidence professionals seeking to build emerging precision medicine infrastructure; less ideal for those prioritizing traditional drug development or near-term clinical validation.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Tempus
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tempus's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Tempus AI's Ascent: A Pharma Validation That Cuts Through the Insider Noise - AD HOC NEWS
Tempus AI's Ascent: A Pharma Validation That Cuts Through the Insider Noise AD HOC NEWS
Tempus AI: Winning With Precision Medicine - Seeking Alpha
Tempus AI: Winning With Precision Medicine Seeking Alpha
Tempus AI's AstraZeneca, BioNTech & Merck Deals — Pharma Demand Keeps Building - Smartkarma
Tempus AI's AstraZeneca, BioNTech & Merck Deals — Pharma Demand Keeps Building Smartkarma
Pharma, Clinical Testing Drive up Personalis Q2 Revenue as Firm Awaits Acquisition by Tempus - GenomeWeb
Pharma, Clinical Testing Drive up Personalis Q2 Revenue as Firm Awaits Acquisition by Tempus GenomeWeb
Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications - Yahoo Finance
Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications Yahoo Finance
Tempus AI model trained on 2.3M slides predicts patient outcomes - Stock Titan
Tempus AI model trained on 2.3M slides predicts patient outcomes Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Evaluation of radiomics and radiologic signatures for diagnosis and clinical outcomes in pancreatic adenocarcinoma and pancreatic neuroendocrine: A pilot study.
Identification of a novel class of early exon ALK rearrangements across two pan-tumor sequencing databases.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo